港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

江西生物

8.970

+0.0600.67%

成交量：25.65万

成交额：227.30万

市值：27.66亿

市盈率：25.75

高：9.305

开：9.050

低：8.500

收：8.910

52周最高：21.100

52周最低：3.950

股本：3.08亿

香港流通股本：3.07亿

量比：0.23

换手率：0.08%

股息：- -

股息率：- -

每股收益(LYR):0.348

净资产收益率：21.04%

总资产收益率：12.08%

市净率：2.80

市盈率(LYR):25.75

市销率: 10.78

数据加载中...

总览公司新闻资讯公告

江西生物跌破发行价：超90%收入来自单一产品，预计2026年净利润大幅下滑

【特约大V】邓声兴：美第三季度开局不利，恒指或随外围走低

江西生物上市首日即破发，业绩增长难挽市场信心，基石投资者被套

深圳商报·读创

董事长年仅33岁，江西生物港股上市，首日破发跌12.68%

红星资本局

江西生物（6915.HK）今日上市：瞄准感染性防治千亿赛道，中国抗血清龙头进击的“默沙东模式”

《股市简讯》中国手术机器人企业真健康医疗香港首秀飙涨197%

异动解读｜江西生物盘中下跌17.86%，新股首日上市开盘即破发

异动解读 | 新股江西生物首日上市盘中大跌近30%，开盘即破发

新股首日 | 江西生物(06915)首挂上市早盘低开33.93% 公司是中国及全球最大的人用TAT提供商

江西生物(06915)：每股定价11.2港元香港公开发售获476.56倍认购

江西生物全球发售最终发售价定为每股H股11.2港元

认购近477倍！江西生物H股公开发售火爆，6月30日正式登陆港交所

新股暗盘 | 江西生物(06915)暗盘盘初跌逾10% 每手亏600港元

老虎暗盘 | 江西生物涨超33%、鲟龙科技涨超85%、来福谐波涨超29%、真健康医疗-B涨超122%

老虎资讯综合

江西生物计划将香港IPO定价为每股11.20港元。

新股消息 | 江西生物(06915)招股结束孖展认购额录得104亿港元超购219倍

江西生物港股IPO：市占率超六成也难掩增利困境增值税骤升与单一产品依赖令前景承压

一图看懂江西生物(6915.HK)IPO

BRIEF-江西生物香港H股开始招股，锁定著名科技企业家龚虹嘉为基石投资者

港股"抗血清第一股"江西生物启动招股，预计6月30日挂牌上市

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/stock/06915/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"06915","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06915\",,,,,undefined,":{"symbol":"06915","market":"HK","secType":"STK","nameCN":"江西生物","latestPrice":8.97,"timestamp":1791876637334,"preClose":8.91,"halted":0,"volume":256500,"delay":0,"changeRate":0.00673400673400679,"floatShares":307000000,"shares":308377319,"eps":0.348324,"marketStatus":"交易中","change":0.06,"latestTime":"10-13 15:35:34","open":9.05,"high":9.305,"low":8.5,"amount":2272990,"amplitude":0.090348,"askPrice":9.035,"askSize":1500,"bidPrice":8.95,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":0.27,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1791879000000},"marketStatusCode":2,"adr":0,"listingDate":1782748800000,"exchange":"SEHK","adjPreClose":8.91,"openAndCloseTimeList":[[1791855000000,1791864000000],[1791867600000,1791878400000]],"volumeRatio":0.230419,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"06915\",,,,,undefined,":{"symbol":"06915","floatShares":307000000,"roa":"12.08%","roe":"21.04%","lyrEps":0.348324,"volumeRatio":0.230419,"shares":308377319,"dividePrice":0,"high":9.305,"amplitude":0.090348,"preClose":8.91,"low":8.5,"week52Low":3.95,"pbRate":"2.80","psRate":"10.78","week52High":21.1,"institutionHeld":0,"latestPrice":8.97,"committee":-0.2,"eps":0.348324,"divideRate":0,"volume":256500,"delay":0,"ttmEps":0.27,"open":9.05,"prevYearClose":11.2,"prevWeekClose":10.9,"prevMonthClose":10.57,"prevQuarterClose":10.57,"fiveDayClose":10.29,"twentyDayClose":14.77,"sixtyDayClose":8.95},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/06915\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"06915","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"06915\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"06915\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1787328000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/06915\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"06915","date":"2026-10-12","current":33.222222,"percent":0.314286,"low":11.368674,"twenty":25.337473,"median":40.447775,"eighty":50.488915,"high":64.851283,"avg":38.671347,"sd":14.304267,"marketCap":2747641912},"quantilePoints":[{"date":"2026-07-03","current":17.947787,"twenty":17.790004,"median":17.849172,"eighty":17.908341,"marketCap":1964363522},{"date":"2026-07-10","current":12.666339,"twenty":12.041485,"median":13.811255,"eighty":17.137167,"marketCap":1384614162},{"date":"2026-07-17","current":19.086739,"twenty":12.428421,"median":14.247428,"eighty":17.908341,"marketCap":2093881996},{"date":"2026-07-24","current":36.000914,"twenty":12.671426,"median":17.750558,"eighty":25.299158,"marketCap":3950313456},{"date":"2026-07-31","current":42.889169,"twenty":12.691776,"median":19.086739,"eighty":36.000914,"marketCap":4715089207},{"date":"2026-08-07","current":26.960254,"twenty":13.811255,"median":25.241686,"eighty":35.873669,"marketCap":2969673581},{"date":"2026-08-14","current":39.144998,"twenty":14.683601,"median":26.960254,"eighty":38.662714,"marketCap":4317282466},{"date":"2026-08-21","current":44.63849,"twenty":14.976114,"median":28.865244,"eighty":39.214557,"marketCap":4934037104},{"date":"2026-08-28","current":57.180101,"twenty":17.750558,"median":31.056328,"eighty":42.629759,"marketCap":6321735039},{"date":"2026-09-04","current":64.851283,"twenty":17.947787,"median":35.937292,"eighty":47.14961,"marketCap":5472349484},{"date":"2026-09-11","current":56.71429,"twenty":19.086739,"median":38.662714,"eighty":50.236386,"marketCap":4792183537},{"date":"2026-09-18","current":59.410336,"twenty":19.114849,"median":39.179778,"eighty":53.519684,"marketCap":5026550299},{"date":"2026-09-25","current":44.186365,"twenty":24.618846,"median":40.682837,"eighty":53.519684,"marketCap":3731365559},{"date":"2026-10-02","current":41.221492,"twenty":25.040488,"median":41.221492,"eighty":53.27527,"marketCap":3484663704},{"date":"2026-10-09","current":39.712768,"twenty":25.299158,"median":40.552653,"eighty":51.033965,"marketCap":3361312777},{"date":"2026-10-12","current":32.407588,"twenty":25.337473,"median":40.447775,"eighty":50.488915,"marketCap":2747641912}],"updateTime":1791876934349},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"06915\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2648793475","title":"江西生物跌破发行价：超90%收入来自单一产品，预计2026年净利润大幅下滑","url":"https://stock-news.laohu8.com/highlight/detail?id=2648793475","media":"蓝鲸财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648793475?lang=zh_cn&edition=fundamental","pubTime":"2026-07-02 12:33","pubTimestamp":1782966800,"startTime":"0","endTime":"0","summary":"蓝鲸新闻7月5日讯6月30日，老牌生物制品企业江西生物（06915.HK）登陆港交所主板，上市首日便遭遇破发。公司发行价11.20港元，收盘报9.78港元/股，单日跌幅12.68%。今日（7月2日），江西生物股价再度下跌，截至收盘，跌幅超过22%，午间收盘报7.54港元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607023791668820.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607023791668820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2648578018","title":"【特约大V】邓声兴：美第三季度开局不利，恒指或随外围走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2648578018","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648578018?lang=zh_cn&edition=fundamental","pubTime":"2026-07-02 09:45","pubTimestamp":1782956725,"startTime":"0","endTime":"0","summary":"国指跌47点或0.62%，报7558点。科指升79点或1.8%，报4472点。美第三季度开局不利，恒指或随外围走低。小分子D&M业务收入69.3亿元，按年激增80.1%，创单季历史新高；TIDES业务收入23.8亿元，客户数与服务分子数分别按年提升28%及59%，公司预计全年TIDES收入增长约40%。截至3月底，持续经营业务在手订单达597.7亿元，按年增长23.6%，为未来增长奠定坚实基础。考虑到公司CRDMO龙头地位、小分子D&M强劲增长及TIDES业务爆发潜力，估值仍具向上修复空间。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/NmQyMzI4NWZmMGRlNDRmMTg4YmIyOTUwMDI3OTAzODMzODA5NjYxNDI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmQyMzI4NWZmMGRlNDRmMTg4YmIyOTUwMDI3OTAzODMzODA5NjYxNDI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984931","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1576","LU0708995583.HKD","03419","06715","03115","07500","LU0348766576.USD","BK1141","07200","09115","513600","02833","LU2045819591.USD","603259","HSI","HSTECH","LU0052750758.USD","MCHmain","LU1046422090.SGD","06915","03037","02800","LU2242644610.SGD","HHImain","02697","LU2125910500.SGD","83115","BK1583","82800","LU0320764599.SGD","02359","07300","03952","LU0348767384.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648779568","title":"江西生物上市首日即破发，业绩增长难挽市场信心，基石投资者被套","url":"https://stock-news.laohu8.com/highlight/detail?id=2648779568","media":"深圳商报·读创","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648779568?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 23:47","pubTimestamp":1782834433,"startTime":"0","endTime":"0","summary":"江西生物制品研究所股份有限公司（简称“江西生物”，股票代码：06915.HK）于6月30日正式在港交所挂牌交易。然而，这家中国内地最大的人用破伤风抗毒素（人用TAT）提供商和出口商，上市首日便遭遇股价“滑铁卢”，开盘即宣告破发。开盘即破发，基石投资者损失千万根据公开信息，江西生物此次IPO最终发行价定为每股11.2港元，全球发售3623.45万股，募资总额约为4亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606303788764283.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303788764283.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IPOS","06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647753079","title":"董事长年仅33岁，江西生物港股上市，首日破发跌12.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647753079","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647753079?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 19:01","pubTimestamp":1782817264,"startTime":"0","endTime":"0","summary":"6月30日，又一家医药企业江西生物（06915.HK）实现在港上市，但上市首日就破发，发行价为11.20港元，截至收盘稿股价报9.78港元，跌幅12.68%。招股书显示，江西生物的历史可追溯至1969年成立的卫生部上海生物制品研究所江西分所，是国内最早布局抗血清领域的生物制品企业之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606303788502573.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606303788502573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06915","VXUS","BK4585","IPOS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647712586","title":"江西生物（6915.HK）今日上市：瞄准感染性防治千亿赛道，中国抗血清龙头进击的“默沙东模式”","url":"https://stock-news.laohu8.com/highlight/detail?id=2647712586","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647712586?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 10:20","pubTimestamp":1782786035,"startTime":"0","endTime":"0","summary":"未来，随着抗感染上升为国家战略级议题，随着被动免疫从“补充手段”跃升为“关键防线”，江西生物的长期价值有望更上一层。","market":"us","thumbnail":"https://img2.gelonghui.com/d273d-7c0026fc-561e-4858-87c9-3a36652f5885.jpg?guru_height=855&guru_width=1280&guru_size=118253","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/d273d-7c0026fc-561e-4858-87c9-3a36652f5885.jpg?guru_height=855&guru_width=1280&guru_size=118253"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/5386488","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647864595","title":"《股市简讯》中国手术机器人企业真健康医疗香港首秀飙涨197%","url":"https://stock-news.laohu8.com/highlight/detail?id=2647864595","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647864595?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 10:14","pubTimestamp":1782785677,"startTime":"0","endTime":"0","summary":"《股市简讯》中国手术机器人企业真健康医疗香港首秀飙涨197%* 中国经皮穿刺手术机器人企业--真健康医疗2697.HK周二香港首日挂牌盘中飙涨197%，触及375.4港元，市值133亿港元。* 该公司以招股价126.2港元上市集资4.5亿港元，公开发售及国际配售分别获1,708倍及1.2倍超额认购。* 据招股书，该公司致力于为精准、微创的肿瘤诊疗提供解决方案，并拥有包含多项国内及全球首创的经皮穿刺与消融产品组合。* 香港股市恒生指数.HSI盘中跌1.1%。（完）更多股市简讯请点选CN-CMN-HOT","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nL4T432067:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915","02697"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189454255","title":"异动解读｜江西生物盘中下跌17.86%，新股首日上市开盘即破发","url":"https://stock-news.laohu8.com/highlight/detail?id=1189454255","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189454255?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 09:50","pubTimestamp":1782784206,"startTime":"0","endTime":"0","summary":"6月30日，江西生物盘中下跌17.86%，报9.08港元，成交额1.04亿港元。消息面上，公司今日以每股11.2港元的发行价正式在港交所主板挂牌，首日开盘即大幅破发。此前暗盘阶段该股已跌破发行价，收报10.54港元，较发行价下跌5.89%。尽管香港公开发售获约476.56倍超额认购，但市场对其单一产品高度依赖、增值税新政冲击利润等风险存在担忧，叠加新股获利了结压力，首日表现持续疲弱。江西生物是中国及全球最大的人用破伤风抗毒素提供商，国内市场份额达65.8%，产品出口至30余个国家和地区。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114651545","title":"异动解读 | 新股江西生物首日上市盘中大跌近30%，开盘即破发","url":"https://stock-news.laohu8.com/highlight/detail?id=1114651545","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114651545?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 09:36","pubTimestamp":1782783401,"startTime":"0","endTime":"0","summary":"江西生物今日盘中股价大跌29.82%，引起了市场的广泛关注。消息面上，江西生物今日正式在港股挂牌上市。根据相关报道，该股上市首日开盘即大幅低开，早盘表现疲弱。作为新股，其上市初期的价格波动通常受到市场情绪、发行定价与投资者获利了结等多重因素影响，首日破发并大幅走低是导致盘中股价急挫的直接原因。江西生物是全球领先的抗血清企业，也是中国及全球最大的人用破伤风抗毒素提供商。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647585902","title":"新股首日 | 江西生物(06915)首挂上市 早盘低开33.93% 公司是中国及全球最大的人用TAT提供商","url":"https://stock-news.laohu8.com/highlight/detail?id=2647585902","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647585902?lang=zh_cn&edition=fundamental","pubTime":"2026-06-30 09:21","pubTimestamp":1782782486,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，江西生物首挂上市，公告显示，每股定价11.2港元，共发行3623.45万股股份，每手500股，所得款项净额约3.39亿港元。招股书显示，江西生物是中国最大的人用破伤风抗毒素提供商和出口商，也是全产业链贯通的抗血清平台商。根据弗若斯特沙利文的资料，公司是中国及全球最大的人用TAT提供商，按2024年销量计，市场份额分别为65.8%及36.6%。于2025年，公司的人用TAT总销量为2990万支，其中在中国销售1350万支，向海外市场出口1640万支。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460911.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06915","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647372693","title":"江西生物(06915)：每股定价11.2港元 香港公开发售获476.56倍认购","url":"https://stock-news.laohu8.com/highlight/detail?id=2647372693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647372693?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 21:23","pubTimestamp":1782739417,"startTime":"0","endTime":"0","summary":"智通财经APP讯，江西生物(06915)公布配发结果，公司全球发售3623.45万股股份，香港公开发售占10%，国际发售占90%。最终发售价为每股11.2港元，全球发售净筹约3.388亿港元。每手500股，预期H股将于2026年6月30日(星期二)上午九时正(香港时间)于联交所开始买卖。其中，香港公开发售获476.56倍认购，国际发售获4.25倍认购。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460653.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151055377","title":"江西生物全球发售最终发售价定为每股H股11.2港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1151055377","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151055377?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 21:19","pubTimestamp":1782739173,"startTime":"0","endTime":"0","summary":"江西生物制品研究所宣布，其全球发售的最终发售价已确定为每股H股11.2港元。这一定价标志着该公司即将在香港联交所完成上市进程。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188842813","title":"认购近477倍！江西生物H股公开发售火爆，6月30日正式登陆港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=1188842813","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188842813?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 21:16","pubTimestamp":1782738999,"startTime":"0","endTime":"0","summary":"江西生物製品研究所股份有限公司完成H股全球发售并将于2026年6月30日在香港联合交易所有限公司主板挂牌交易，股份代号6915。公司以每股11.20港元定价，合计发行36,234,500股H股，募得资金总额约4.06亿港元，扣除相关费用后净筹3.39亿港元。香港公开发售部分获78,433份有效申请，录得约476.56倍超额认购，并未触发回补机制，最终分配3,623,500股H股，占全球发售总量10%。江西生物成功完成全球发售并即将挂牌，标志着公司正式登陆国际资本市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647535324","title":"新股暗盘 | 江西生物(06915)暗盘盘初跌逾10% 每手亏600港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647535324","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647535324?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 16:22","pubTimestamp":1782721370,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，江西生物(06915)将于6月30日(周二)在香港挂牌。截至发稿，暗盘交易显示报价10港元，较招股价11.2港元下跌10.71%，每手500股，不计手续费，每手亏600港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460295.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114495509","title":"老虎暗盘 | 江西生物涨超33%、鲟龙科技涨超85%、来福谐波涨超29%、真健康医疗-B涨超122%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114495509","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114495509?lang=zh_cn&edition=fundamental","pubTime":"2026-06-29 16:08","pubTimestamp":1782720490,"startTime":"0","endTime":"0","summary":"6月29日，江西生物暗盘涨超33%，总市值超46亿港元，每股定价11.2港元，每手500股；鲟龙科技暗盘涨超85%，总市值超152亿港元，每股定价75.5港元，每手100股；来福谐波暗盘涨超29%，总市值超114亿港元，每股定价85.5港元，每手100股；真健康医疗-B暗盘涨超122%，总市值超100亿港元，每股定价126.2港元，每手20股；上述四家公司将于6月30日（周二）正式在港交所挂牌交易。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06915","06715","02697","03952"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646380064","title":"江西生物计划将香港IPO定价为每股11.20港元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2646380064","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646380064?lang=zh_cn&edition=fundamental","pubTime":"2026-06-26 10:03","pubTimestamp":1782439438,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["EWH","06915","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646242468","title":"新股消息 | 江西生物(06915)招股结束 孖展认购额录得104亿港元 超购219倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2646242468","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646242468?lang=zh_cn&edition=fundamental","pubTime":"2026-06-25 14:25","pubTimestamp":1782368711,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物医药公司江西生物于2026年6月22日至6月25日招股，最新已结束招股。根据市场消息，江西生物已获券商借出104亿港元孖展，以公开集资额4732万港元计，超购219倍。每股发售价介乎9.33至13.06港元，集资最多4.7亿港元，每手500股，一手入场费6595.9港元。本次IPO，公司引入WSH富策控股为基石投资者，投资金额5000万港元。于2025年，公司的人用TAT总销量为2990万支，其中在中国销售1350万支，向海外市场出口1640万支。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458575.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645867869","title":"江西生物港股IPO：市占率超六成也难掩增利困境 增值税骤升与单一产品依赖令前景承压","url":"https://stock-news.laohu8.com/highlight/detail?id=2645867869","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645867869?lang=zh_cn&edition=fundamental","pubTime":"2026-06-24 14:36","pubTimestamp":1782282960,"startTime":"0","endTime":"0","summary":"中国最大的人用破伤风抗毒素提供商——江西生物制品研究所股份有限公司正式启动港股全球发售。公司凭借高达65.8%的国内市场份额和“全产业链抗血清平台”的稀缺标签，吸引了市场一定关注。然而，在这份行业龙头的叙事之下，然而单品高度集中、原料供给收缩、增值税新政冲击利润、基石支撑薄弱、家族控股等一系列核心风险，为本次IPO带来了多重不确定性。　　本次IPO的基石投资环节，是引发市场质疑的焦点之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-06-24/doc-inientty6313423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","06915","IPOS","BK4585","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645001882","title":"一图看懂江西生物(6915.HK)IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2645001882","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645001882?lang=zh_cn&edition=fundamental","pubTime":"2026-06-23 09:27","pubTimestamp":1782178022,"startTime":"0","endTime":"0","summary":"近日，港股\"抗血清第一股\"江西生物(6915.HK)正式启动招股，预计6月30日挂牌上市。下面将以一图看懂江西生物IPO。","market":"sh","thumbnail":" http://caiji.3g.cnfol.com/colect/202606/23/20260623755224.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202606/23/20260623755224.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260623/32286496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","06915"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645127970","title":"BRIEF-江西生物香港H股开始招股，锁定著名科技企业家龚虹嘉为基石投资者","url":"https://stock-news.laohu8.com/highlight/detail?id=2645127970","media":"路透中文","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645127970?lang=zh_cn&edition=fundamental","pubTime":"2026-06-22 09:39","pubTimestamp":1782092369,"startTime":"0","endTime":"0","summary":"BRIEF-江西生物香港H股开始招股，锁定著名科技企业家龚虹嘉为基石投资者江西生物制品研究所股份有限公司：* 全球发售3,623.45万股H股，发售价区间为每股9.33-13.06港元，股份代号“6915”，联席保荐人为中金公司以及招商证券国际，香港公开发售由6月22日开始至25日中午截止，预期6月30日在联交所买卖* 我们是中国最大的人用破伤风抗毒素（“人用TAT”）提供商和出口商* 基石投资者","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nL4S42U053:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0089","BK0231","BK0041","688521","06915","BK0100","BK0175","BK0197","BK0010","BK0028","BK0183","BK0196","BK0214","SGXZ49509284.SGD","BK0058","SGXZ81163826.USD","BK0188","002415"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645017888","title":"港股\"抗血清第一股\"江西生物启动招股，预计6月30日挂牌上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2645017888","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645017888?lang=zh_cn&edition=fundamental","pubTime":"2026-06-22 09:26","pubTimestamp":1782091565,"startTime":"0","endTime":"0","summary":"6月22日，江西生物制品研究所股份有限公司于6月22日正式启动招股。据悉，公司拟于6月30日正式在港交所主板挂牌上市。根据弗若斯特沙利文的资料，作为全球领先的抗血清企业，江西生物是全球最大的人用破伤风抗毒素提供商及中国最大的出口商。公司在中国人用TAT市场长期占据主导地位，市场份额连续19年保持在50%以上。","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/06/22092657535501.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["IPOS","BK4585","VXUS","BK4588","06915"],"isVideo":false,"video":null,"gpt_icon":1}],"pageSize":20,"totalPage":5,"pageCount":4,"totalSize":84,"code":"91000000","status":"200"}]}}